Multivariate analysis by LASSO of clinical and genetic variables and GVHD/NRM
| Variable . | Polymorphism . | Genotype . | D/R . | Model of transmission . | OR* . | ||||
|---|---|---|---|---|---|---|---|---|---|
| aGVHD 2-4 . | aGVHD 3-4 . | cGVHD . | Extensive cGVHD . | NRM . | |||||
| Clinical | |||||||||
| Recipient age >45 y | 1.080 | 1.570 | |||||||
| Recipient sex, male vs female | 0.693 | 0.974 | |||||||
| Female donor/male recipient | 1.318 | ||||||||
| AML | 0.858 | ||||||||
| ALL | 1.614 | ||||||||
| MDS | 1.260 | 2.374 | |||||||
| Lymphoma | 1.330 | ||||||||
| Myelofibrosis | 0.640 | ||||||||
| MM | 1.827 | ||||||||
| Conditioning, RIC vs MAC | 0.679 | ||||||||
| Conditioning regimen, TBI vs no TBI | 0.575 | ||||||||
| Stem-cell source, PB vs BM | 1.557 | 2.281 | |||||||
| aGVHD, grade 2-4 | 1.343 | 1.231 | |||||||
| Genetic | |||||||||
| IL-1A | rs1800587 | TC | D | Add | 1.508 | ||||
| TT | R | Rec | 1.058 | ||||||
| IL-1B | rs1143627 | TT | R | Dom | 0.809 | ||||
| CC<CT<TT | D | Add | 1.079 | 1.009 | |||||
| rs16944 | GG | R | Dom | 0.893 | |||||
| AA<AG<GG | D | Add | 1.095 | ||||||
| rs1143634 | TT<CT<CC | R | Add | 0.927 | |||||
| TT | D | Rec | 2.968 | 1.016 | 0.664 | ||||
| IL-2 | rs2069762 | GT | D | Cod | 1.162 | ||||
| GG | R | Rec | 0.248 | 0.848 | 1.107 | 0.800 | |||
| GT | R | Cod | 1.241 | 1.092 | |||||
| IL-6 | rs1800795 | GG | R | Cod | 1.065 | ||||
| GG | R | Dom | 1.664 | ||||||
| CG | R | Cod | 1.557 | ||||||
| CC<CG<GG | R | Add | 0.671 | ||||||
| GG | D | Cod | 0.996 | ||||||
| GG | D | Dom | 0.886 | ||||||
| IL-7R | rs1494555 | CC | R | Rec | 2.007 | ||||
| CT | D | Cod | 0.792 | 1.161 | 0.845 | ||||
| IL-10 | rs1800871 | CT | R | Cod | 3.046 | ||||
| TT | D | Rec | 1.213 | ||||||
| CT | D | Cod | 1.124 | ||||||
| TT<CT<CC | D | Add | 1.002 | ||||||
| rs1800872 | AC | R | Cod | 1.088 | |||||
| rs1800896 | AG | R | Cod | 1.246 | |||||
| AG | D | Cod | 1.139 | ||||||
| IL-17A | rs8193036 | CC | R | Rec | 1.062 | 1.019 | |||
| CC<CT<TT | R | Add | 0.642 | ||||||
| CC | D | Rec | 1.419 | 2.274 | |||||
| CT | D | Cod | 0.611 | ||||||
| rs3819024 | GG | R | Rec | 0.797 | |||||
| GG | D | Rec | 1.126 | 1.222 | |||||
| GG<AG<AA | D | Add | 0.917 | 0.906 | |||||
| rs4711998 | AG | R | Cod | 1.377 | |||||
| GG | R | Dom | 1.346 | ||||||
| AA<AG<GG | D | Add | 0.894 | ||||||
| rs2275913 | AA | R | Rec | 0.085 | 1.267 | ||||
| AA<AG<GG | R | Add | 0.710 | ||||||
| AA | D | Rec | 1.220 | ||||||
| AG | D | Cod | 0.963 | ||||||
| IL-23R | rs6687620 | TT<CT<CC | R | Add | 0.851 | ||||
| CT | R | Cod | 1.671 | ||||||
| TT | R | Rec | 0.702 | 3.827 | |||||
| CC | R | Dom | 0.928 | ||||||
| TT | D | Rec | 0.396 | ||||||
| TT<CT<CC | D | Add | 1.267 | ||||||
| CT | D | Cod | 0.752 | 0.647 | |||||
| rs11209026 | GG | R | Dom | 0.983 | 1.896 | ||||
| AA<AG<GG | R | Add | 0.967 | ||||||
| AA | D | Rec | 2.712 | ||||||
| IFN-γ | rs2430561 | AT | R | Cod | 0.975 | ||||
| AA | R | Rec | 1.745 | ||||||
| AT | D | Cod | 0.751 | ||||||
| rs2069705 | TT | R | Rec | 0.804 | |||||
| CT | R | Cod | 0.997 | ||||||
| TT<CT<CC | R | Add | 0.929 | ||||||
| CC | D | Dom | 0.880 | ||||||
| CT | D | Cod | 1.304 | 1.162 | |||||
| TT | D | Rec | 1.017 | ||||||
| TGFβ | rs2241716 | GG | D | Dom | 0.359 | 0.140 | |||
| GG | D | Cod | 0.839 | ||||||
| AA<AG<GG | D | Add | 0.581 | ||||||
| rs1800469 | TT | R | Rec | 1.201 | |||||
| CC | R | Dom | 0.875 | ||||||
| TT<CT<CC | R | Add | 0.994 | ||||||
| TT | D | Rec | 0.865 | 0.908 | |||||
| CT | D | Cod | 1.008 | ||||||
| TNFα | rs1799964 | CC | R | Rec | 0.968 | ||||
| CC | D | Rec | 1.613 | ||||||
| CC<CT<TT | D | Add | 0.930 | ||||||
| rs1800629 | AG | R | Cod | 3.422 | |||||
| rs361525 | AG | R | Cod | 1.140 | |||||
| GG | D | Dom | 0.948 | ||||||
| Variable . | Polymorphism . | Genotype . | D/R . | Model of transmission . | OR* . | ||||
|---|---|---|---|---|---|---|---|---|---|
| aGVHD 2-4 . | aGVHD 3-4 . | cGVHD . | Extensive cGVHD . | NRM . | |||||
| Clinical | |||||||||
| Recipient age >45 y | 1.080 | 1.570 | |||||||
| Recipient sex, male vs female | 0.693 | 0.974 | |||||||
| Female donor/male recipient | 1.318 | ||||||||
| AML | 0.858 | ||||||||
| ALL | 1.614 | ||||||||
| MDS | 1.260 | 2.374 | |||||||
| Lymphoma | 1.330 | ||||||||
| Myelofibrosis | 0.640 | ||||||||
| MM | 1.827 | ||||||||
| Conditioning, RIC vs MAC | 0.679 | ||||||||
| Conditioning regimen, TBI vs no TBI | 0.575 | ||||||||
| Stem-cell source, PB vs BM | 1.557 | 2.281 | |||||||
| aGVHD, grade 2-4 | 1.343 | 1.231 | |||||||
| Genetic | |||||||||
| IL-1A | rs1800587 | TC | D | Add | 1.508 | ||||
| TT | R | Rec | 1.058 | ||||||
| IL-1B | rs1143627 | TT | R | Dom | 0.809 | ||||
| CC<CT<TT | D | Add | 1.079 | 1.009 | |||||
| rs16944 | GG | R | Dom | 0.893 | |||||
| AA<AG<GG | D | Add | 1.095 | ||||||
| rs1143634 | TT<CT<CC | R | Add | 0.927 | |||||
| TT | D | Rec | 2.968 | 1.016 | 0.664 | ||||
| IL-2 | rs2069762 | GT | D | Cod | 1.162 | ||||
| GG | R | Rec | 0.248 | 0.848 | 1.107 | 0.800 | |||
| GT | R | Cod | 1.241 | 1.092 | |||||
| IL-6 | rs1800795 | GG | R | Cod | 1.065 | ||||
| GG | R | Dom | 1.664 | ||||||
| CG | R | Cod | 1.557 | ||||||
| CC<CG<GG | R | Add | 0.671 | ||||||
| GG | D | Cod | 0.996 | ||||||
| GG | D | Dom | 0.886 | ||||||
| IL-7R | rs1494555 | CC | R | Rec | 2.007 | ||||
| CT | D | Cod | 0.792 | 1.161 | 0.845 | ||||
| IL-10 | rs1800871 | CT | R | Cod | 3.046 | ||||
| TT | D | Rec | 1.213 | ||||||
| CT | D | Cod | 1.124 | ||||||
| TT<CT<CC | D | Add | 1.002 | ||||||
| rs1800872 | AC | R | Cod | 1.088 | |||||
| rs1800896 | AG | R | Cod | 1.246 | |||||
| AG | D | Cod | 1.139 | ||||||
| IL-17A | rs8193036 | CC | R | Rec | 1.062 | 1.019 | |||
| CC<CT<TT | R | Add | 0.642 | ||||||
| CC | D | Rec | 1.419 | 2.274 | |||||
| CT | D | Cod | 0.611 | ||||||
| rs3819024 | GG | R | Rec | 0.797 | |||||
| GG | D | Rec | 1.126 | 1.222 | |||||
| GG<AG<AA | D | Add | 0.917 | 0.906 | |||||
| rs4711998 | AG | R | Cod | 1.377 | |||||
| GG | R | Dom | 1.346 | ||||||
| AA<AG<GG | D | Add | 0.894 | ||||||
| rs2275913 | AA | R | Rec | 0.085 | 1.267 | ||||
| AA<AG<GG | R | Add | 0.710 | ||||||
| AA | D | Rec | 1.220 | ||||||
| AG | D | Cod | 0.963 | ||||||
| IL-23R | rs6687620 | TT<CT<CC | R | Add | 0.851 | ||||
| CT | R | Cod | 1.671 | ||||||
| TT | R | Rec | 0.702 | 3.827 | |||||
| CC | R | Dom | 0.928 | ||||||
| TT | D | Rec | 0.396 | ||||||
| TT<CT<CC | D | Add | 1.267 | ||||||
| CT | D | Cod | 0.752 | 0.647 | |||||
| rs11209026 | GG | R | Dom | 0.983 | 1.896 | ||||
| AA<AG<GG | R | Add | 0.967 | ||||||
| AA | D | Rec | 2.712 | ||||||
| IFN-γ | rs2430561 | AT | R | Cod | 0.975 | ||||
| AA | R | Rec | 1.745 | ||||||
| AT | D | Cod | 0.751 | ||||||
| rs2069705 | TT | R | Rec | 0.804 | |||||
| CT | R | Cod | 0.997 | ||||||
| TT<CT<CC | R | Add | 0.929 | ||||||
| CC | D | Dom | 0.880 | ||||||
| CT | D | Cod | 1.304 | 1.162 | |||||
| TT | D | Rec | 1.017 | ||||||
| TGFβ | rs2241716 | GG | D | Dom | 0.359 | 0.140 | |||
| GG | D | Cod | 0.839 | ||||||
| AA<AG<GG | D | Add | 0.581 | ||||||
| rs1800469 | TT | R | Rec | 1.201 | |||||
| CC | R | Dom | 0.875 | ||||||
| TT<CT<CC | R | Add | 0.994 | ||||||
| TT | D | Rec | 0.865 | 0.908 | |||||
| CT | D | Cod | 1.008 | ||||||
| TNFα | rs1799964 | CC | R | Rec | 0.968 | ||||
| CC | D | Rec | 1.613 | ||||||
| CC<CT<TT | D | Add | 0.930 | ||||||
| rs1800629 | AG | R | Cod | 3.422 | |||||
| rs361525 | AG | R | Cod | 1.140 | |||||
| GG | D | Dom | 0.948 | ||||||
OR values for the variables selected by the LASSO procedure (described in “Methods”). OR values were obtained with the exponential function of β coefficient, which compares the strength of the effect of each individual independent variable with the dependent variable. The higher the absolute value of β, the stronger the effect. β = 0, OR = 1 (neutral); β < 0, OR < 1 (L); β > 0, OR > 1 (H).